Bicyclic peptide conjugate therapy for bladder cancer achieves 50% objective response rate

Bicycle Therapeutics today announced the latest clinical trial results of its investigational bicyclic peptide-based therapy BT8009 at the AACR Annual Meeting

Bicyclic peptide technology incorporates chemical modifications into polypeptides to form a fixed three-dimensional molecular conformation

▲Characteristic comparison of bicyclic peptides with small molecules and antibodies (Image source: Bicycle Therapeutics official website)

In this clinical trial, 49% of patients with solid tumors who had received an average of 3 prior therapies and received different doses of BT8009 were patients with urothelial carcinoma

▲Trial data of BT8009 in the treatment of patients with urothelial carcinoma (5.

In terms of safety, no dose-limiting toxicities were found in the 2.

"We believe the differentiated pharmacokinetic profile of bicyclic peptide-conjugated toxins has the potential to lead to better patient outcomes," said Bicycle CEO Dr.

References:

[1] Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting.